Alkermes plc

NASDAQ: ALKS
$27.70
-$0.21 (-0.8%)
Closing Price on November 21, 2024

ALKS Stock Chart and Intraday Price

ALKS Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, IE
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 5,052.38M USD
Shares Outstanding 167,076,000
Alkermes plc is a biopharmaceutical company based in Dublin, Ireland, focusing on developing treatments for critical unmet medical needs. It specializes in creating innovative therapies for alcohol and opioid dependence, schizophrenia, bipolar I disorder, and other neurological disorders. Its product lineup includes ARISTADA and VIVITROL, among others, aimed at improving patient outcomes. Alkermes also collaborates with leading pharmaceutical companies and leverages proprietary technology platforms to advance its research and development efforts, making significant contributions to the field of medicine since its establishment in 1987.

ALKS Articles

Wednesday's top analyst upgrades and downgrades included Ally Financial, Applied Materials, CrowdStrike, Fidelity National Information Services, First Solar, Fortinet, Newmont, Occidental Petroleum,...
Thursday's additional analyst upgrades and downgrades were on Alkermes, Altice USA, Fisker, Freshpet, Lincoln National, Maravai LifeSciences and more.
Friday’s additional top analyst upgrades and downgrades were on Alkermes, AppLovin, Delta Air Lines, Micron Technology, Stanley Black & Decker and more.
Wednesday’s top analyst upgrades and downgrades included Apple, Carvana, Elanco Animal Health, Gilead Sciences, Home Depot, Park Hotels & Resorts, Shoals Technologies, SNDL, SITE Centers and UDR.
Friday’s additional top analyst upgrades and downgrades included Alkermes, Callaway Golf, Canadian National Railway, Electronic Arts, Kroger and Union Pacific.
Thursday's top analyst upgrades and downgrades included Bed Bath & Beyond, Block, Citizens Financial, DoorDash, Exelon, Exxon Mobil, Halliburton, Kinross Gold, Lockheed Martin, Matador Resources,...
Thursday afternoon's top analyst upgrades and downgrades included Equifax, Corning, Iridium Communications, KB Home and Tesla.
Wednesday’s top analyst upgrades and downgrades included Beyond Meat, Capital One, Decker's Outdoors, Diageo, DoorDash, Foot Locker, Krispy Kreme, MP Materials, Redbox Entertainment, Shift4...
Thursday's top analyst upgrades and downgrades included AT&T, Alibaba, Ally Financial, BioMarin Pharmaceutical, Box, Citrix Systems, Nio, Schlumberger and TJX Companies.
Thursday’s top analyst upgrades and downgrades included Advanced Micro Devices, Alkermes, Clover Health, Okta, Peloton Interactive, Starbucks and Unilever.
Thursday's top analyst upgrades and downgrades included Alkermes, Amazon.com, Citigroup, eBay, Fastly, Groupon, Lyft, Netflix, ONEOK, Roku, Uber Technologies and Zoom Video Communications.
Friday's top analyst upgrades, downgrades and initiations included Alkermes, Aurora Cannabis, BlackRock, Duke Energy, Nvidia, Ralph Lauren, SunPower, Veeva Systems and Yelp.
Biogen and Alkermes have announced that the FDA approved Vumerity for the treatment of relapsing forms of multiple sclerosis.
Alkermes shares made a handy gain on Monday after the firm announced that it would be expanding its New Drug Application for ALKS 3831 to encompass the treatment of bipolar I disorder in addition to...
The top analyst upgrades, downgrades and initiations on Monday included Agilent Technologies, Amazon.com, American Water Works, Crocs, Deere, General Electric, Gilead Sciences, Slack and Teva...